Bladder Cancer VL

EAU Guidelines on Non-Muscle-Invasive Bladder Cancer 2020 Update - Marek Babjuk

Details
The European Association of Urology (EAU) published its updated guideline recommendations for non-muscle invasive bladder cancer (NMIBC) in 2020. The updated EAU Guidelines stratify NMIBC into low, intermediate, and high risk for treatment options. In this conversations with Ashish Kamat, MD, MBBS, Marko Babjuk, MD, Ph.D., overviews the 2020 updated guidelines highlighting changes in the guideline...

DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt

Details
Alexander Wyatt from the University of British Columbia joins Ashish Kamat in a discussion on the genomic correlates of Bacillus Calmette-Guerin (BCG) responsive and relapsed non-muscle invasive bladder cancer. Dr. Wyatt shares recent study findings exploring links between common genomic driver alternations and BCG unresponsiveness and also data looking at genomic variables in the context of initi...

Pembrolizumab in High-Risk, BCG Unresponsive Non-Muscle Invasive Bladder Cancer - Arjun Balar

Details
In this conversation with Ashish Kamat, MD, Arjun Balar, MD, MBBS, discusses testing the concept of effectively treating bladder cancer without needing chemotherapy in the non-muscle-invasive disease space, specifically patients with high-risk carcinoma in situ, with or without papillary tumors that had become unresponsive to Bacillus Calmette-Guerin (BCG) based on the current Federal Drug Adminis...

A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse

Details
Ashish Kamat welcomes Karen Sachse, a patient advocate for the Bladder Cancer Advocacy Network (BCAN) who shares her perspective on non muscle-invasive bladder cancer, the various trials that are ongoing, and the future of various studies. As a bladder cancer survivor diagnosed in 2010 at age 54 with high grade non-muscle invasive bladder cancer, she is disease-free since 2014. Biographies: Karen...

How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black

Details
Co-chair of the Bacillus Calmette Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer session during the 2020 Virtual Bladder Cancer Advocacy Network Think Tank (BCANTT) meeting, Peter Black, MD joins Ashish Kamat, MD, MBBS providing a succinct overview of this session highlighting the clinical and the translational panel which addresses defining treatment failure after BCG treatment for...

High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi

Details
Bacillus Calmette-Guerin (BCG) has been the standard of care for patients with non muscle-invasive bladder cancer for decades. However, within five years of the first instillation of BCG therapy, about 50% of tumors recur, and 20% of tumors will progress. To overcome BCG resistance, we need to understand the mechanisms of a BCG therapeutic effect and identify molecular correlates that can predict...

Vicineum for High-Risk Non-Muscle-Invasive BCG Unresponsive Bladder Cancer - Rian J. Dickstein

Details
Rian Dickstein, MD, FACS, joins Ashish Kamat, MD, MBBS proving a background of the use of Vicineum® for patients with bacillus calmette-guerin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). Vicineum is a recombinant fusion protein antibody linked to a variant of pseudomonas exotoxin A (ETA) which is administered intravesically for 2 hours twice weekly with induction x 6 w...

The Role of the PD-L1 Checkpoint in BCG Resistance - Max Kates

Details
An augmented presentation from the Bladder Cancer Advocacy Network’s (BCAN) Think Tank 2020 — talk by and discussion with Dr Max Kates PD-L1 was found to be a mediator of bladder-cancer stage progression in a 2007 Mayo Clinic study by Inman et al. A primary observation was that as local tumor stage advanced, levels of PD-L1 expressed by tumor cells increased. Another key discovery was that the maj...

Variant Histology Urothelial Carcinoma: A Patient Case - Makarand Khochikar

Details
Ashish Kamat, MD, welcomes Makarand Khochikar, President of the Urological Society of India – West zone and Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital in Miraj joins to discuss a bladder cancer case from Dr. Khockikar’s case files. In this particular case, Dr. Khockikar reviews the cystoscopy of a 65-year-old male presented with intermittent hematuria and...

T2 N0 M0 High-grade Urothelial Carcinoma Patient Case Study with Cushingoid Features Undergoing Radical Cystectomy in Neobladder - Makarand Khochikar

Details
In a conversation with Ashish Kamat, MD, MBBS, Makarand Khochikar, MS DNB, Dip. Urol, FRCS, FEBU, presents a bladder cancer case study focusing on a patient with invasive T2 N0 M0 high-grade urothelial carcinoma. Dr. Khochikar describes both the process of perioperative counseling with the patient and the radical cystectomy that was surgically performed. Dr. Khochikar walks through the procedure a...